Febbo PG - Search Results

1

Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors.

Alvarez JV, Febbo PG, Ramaswamy S, Loda M, Richardson A, Frank DA. Alvarez JV, et al. Among authors: febbo pg. Cancer Res. 2005 Jun 15;65(12):5054-62. doi: 10.1158/0008-5472.CAN-04-4281. Cancer Res. 2005. PMID: 15958548

2

Gene expression correlates of clinical prostate cancer behavior.

Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Singh D, et al. Among authors: febbo pg. Cancer Cell. 2002 Mar;1(2):203-9. doi: 10.1016/s1535-6108(02)00030-2. Cancer Cell. 2002. PMID: 12086878 Free article.

3

Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model.

Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, Xue Q, Bikoff R, Ma H, Kantoff PW, Golub TR, Loda M, Sellers WR. Majumder PK, et al. Among authors: febbo pg. Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7841-6. doi: 10.1073/pnas.1232229100. Epub 2003 Jun 10. Proc Natl Acad Sci U S A. 2003. PMID: 12799464 Free PMC article.

4

Fatty acid synthase expression defines distinct molecular signatures in prostate cancer.

Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M. Rossi S, et al. Mol Cancer Res. 2003 Aug;1(10):707-15. Mol Cancer Res. 2003. PMID: 12939396

5

Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP.

Lieberfarb ME, Lin M, Lechpammer M, Li C, Tanenbaum DM, Febbo PG, Wright RL, Shim J, Kantoff PW, Loda M, Meyerson M, Sellers WR. Lieberfarb ME, et al. Among authors: febbo pg. Cancer Res. 2003 Aug 15;63(16):4781-5. Cancer Res. 2003. PMID: 12941794

6

Use of expression analysis to predict outcome after radical prostatectomy.

Febbo PG, Sellers WR. Febbo PG, et al. J Urol. 2003 Dec;170(6 Pt 2):S11-9; discussion S19-20. doi: 10.1097/01.ju.0000095567.03807.a1. J Urol. 2003. PMID: 14610405

7

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.

Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR. Majumder PK, et al. Among authors: febbo pg. Nat Med. 2004 Jun;10(6):594-601. doi: 10.1038/nm1052. Epub 2004 May 23. Nat Med. 2004. PMID: 15156201

8

Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells.

Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, Signoretti S, Campbell KT, Sellers WR, Roberts TM, Loda M, Golub TR, Hahn WC. Berger R, et al. Among authors: febbo pg. Cancer Res. 2004 Dec 15;64(24):8867-75. doi: 10.1158/0008-5472.CAN-04-2938. Cancer Res. 2004. PMID: 15604246

9

Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer.

Febbo PG, Lowenberg M, Thorner AR, Brown M, Loda M, Golub TR. Febbo PG, et al. J Urol. 2005 May;173(5):1772-7. doi: 10.1097/01.ju.0000155845.44729.ba. J Urol. 2005. PMID: 15821585

10

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.

Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK. Febbo PG, et al. Clin Cancer Res. 2005 Jul 15;11(14):5233-40. doi: 10.1158/1078-0432.CCR-05-0299. Clin Cancer Res. 2005. PMID: 16033841 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

104 results

Search Page

Filters